P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2018-09, Vol.20 (suppl_3), p.iii240-iii240
• Main Authors: Hagemann, C, Neuhaus, N, Dahlmann, M, Kessler, A F, Kobelt, D, Herrmann, P, Eyrich, M, Freitag, B, Linsenmann, T, Monoranu, C M, Ernestus, R, Löhr, M, Stein, U
• Format: Article
• Language: English
• Subjects: Poster Presentations
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noy139.092

Abstract Background IDH1-mutation and MGMT-promoter methylation are established prognostic markers in glioblastoma multiforme (GBM); however, invasive procedures are needed to obtain the required tumor tissue. Metastasis-associated in colon cancer-1 (MACC1) has been established as a prognostic plasma marker for several solid cancer entities. Here, we evaluated circulating MACC1 transcripts for prediction of clinical outcome and therapy response in GBM. Material and Methods Plasma samples were collected from 45 GBM patients (31 IDH1 wildtype (wt), 5 IDH1R132H, 9 unspecified) before surgery. The patients’ clinical course was followed for 24 months. Samples from 15 healthy volunteers served as controls. MACC1-transcript levels, determined by qRT-PCR, were correlated with patient overall survival (OS) and clinical data of known prognostic significance. Cut-off values for Kaplan-Meier analyses were determined by ROC calculations. Cluster analyses were performed. Results MACC1 transcripts were higher in patients plasma compared to healthy controls (P